The BioRevolution 2024 Superconvergence Series: A Successful Gene Therapy?

By Christopher Gannatti, CFA, Global Head of Research Key Takeaways The biotech sector has not seen sustained growth in 2024 despite initial optimism and continued progress. Sarepta Therapeutics’ Elevidys, a $3.2 million gene therapy for Duchenne muscular dystrophy, received expanded FDA approval in June 2024, with positive indications of insurance coverage a key (…)

BioRevolution Superconvergence series post 2024: A successful gene therapy? appeared first on ETF Trends.